Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Dental Products Panel to Consider Amalgam, Mercury Safety Issues

December 10, 2010 2:32 pm | by U.S. Food & Drug Administration | News | Comments

The FDA’s Dental Products Panel will be asked this week to consider what scientific methodology is needed to determine unsafe levels of dental amalgam and mercury, especially for children and other vulnerable patients.

TOPICS:

CDRH Explains Itself as Ethicon Prepares to Defend Its Sedasys(2)

December 10, 2010 2:32 pm | by U.S. Food & Drug Administration | News | Comments

As Johnson & Johnson (J&J) subsidiary Ethicon Endo-Surgery prepares to defend its computer-assisted personalized sedation system before an independent advisory panel convened by FDA Commissioner Margaret Hamburg, CDRH is finally explaining why it rejected the Sedasys device in the...

TOPICS:

CDRH Explains Itself as Ethicon Prepares to Defend Its Sedasys

December 10, 2010 2:31 pm | News | Comments

As Johnson & Johnson (J&J) subsidiary Ethicon Endo-Surgery prepares to defend its computer-assisted personalized sedation system before an independent advisory panel convened by FDA Commissioner Margaret Hamburg, CDRH is finally explaining why it rejected the Sedasys device in the...

Advertisement

Summary Box: Analysts criticize Tenet deal price

December 10, 2010 1:45 pm | by The Associated Press | News | Comments

THE OPINION: Analysts say Community Health Systems Inc.'s $3 billion offer for Tenet Healthcare Corp. is too low but might inspire other suitors to start a bidding war.DEAL DETAILS: Community Health has offered $5 in cash and $1 in stock per Tenet share, marking a 40 percent premium to Tenet's last...

Thornridge takes stake in Assisted Living

December 10, 2010 12:45 pm | by The Associated Press | News | Comments

Senior living facility operator Assisted Living Concepts Inc. said Friday its largest shareholder, Scotia Investments Ltd., has transferred its shares to a former affiliate, Thornridge Holdings Ltd.The transfer is part of the reorganization by Scotia Investments.Assisted Living said it doesn't...

Phase III Efficacy Data on Bevacizumab Plus Chemotherapy in Early Breast Cancer to be Presented

December 10, 2010 12:34 pm | by AACR | News | Comments

SAN ANTONIO - Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

TOPICS:

Stryker adds board member, bringing total to 10

December 10, 2010 11:45 am | by The Associated Press | News | Comments

Medical equipment maker Stryker Corp. said Friday that it has hired Allan C. Golston, who heads the U.S. arm of the Bill & Melinda Gates Foundation, as a director.The move expands Stryker's board to 10 members."Allan's experience as a hospital finance executive, combined with his Gates...

Agrivida, Syngenta aim for low-cost sugar production

December 10, 2010 10:33 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Agrivida Inc., a Medford-based developer of new crop varieties for biofuels production, is working with Syngenta Ventures to create new forms of corn and switchgrass, among other crops, that will provide low-cost sugar for industrial use.

Advertisement

Maximizing the Potential of Multi-Drug Portfolios Without Cannibalizing from a Legacy Brand

December 10, 2010 10:33 am | by Bio-Medicine.Org | News | Comments

CHAPEL HILL, N.C., Dec. 10, 2010 /- Managing multiple brands for the same indication is a complex balancing act for bio-pharmaceutical companies. While a new product can translate into expanded market share and improved reputation with physicians, it can also result in a new product...

TOPICS:

Hanger Orthopedic shareholder plans $40M sale

December 10, 2010 9:45 am | by The Associated Press | News | Comments

Hanger Orthopedic Group Inc. said Friday that investor Ares Corporate Opportunities Fund is selling 2 million shares of Hanger stock for $20 per share.Hanger won't get any of the proceeds from the sale, which is expected to close Wednesday. The company said the shares were issued to Ares in...

BioVex launches Phase 3 study on head and neck cancer treatment

December 10, 2010 9:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Woburn-based biotech company BioVex Inc. today said that it has launched a Phase 3 study of its OncoVEXGM-CSF as a treatment for patients with locally advanced squamous cell carcinoma of the head and neck.

Molecular Insight files for Ch. 11

December 10, 2010 9:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Molecular Insight Pharmaceuticals, Inc. has filed for chapter 11 bankruptcy protection, in a deal that will secure the company a $45 million cash infusion from a private investment company.

Tomophase lung imaging device gets FDA OK

December 10, 2010 9:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

The U.S. Food and Drug Administration has granted 510(k) marketing clearance for Tomophase Corp.'s non-invasive Optical Coherence Tomography Imaging System (OCTIS).

Circulating Tumor Cells Predicted Recurrence, Death in Patients with Early-stage Breast Cancer

December 10, 2010 9:32 am | by AACR | News | Comments

SAN ANTONIO - The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III...

TOPICS:

High CTC Levels Predicted Poor Outcome in Metastatic Breast Cancer

December 10, 2010 9:31 am | by AACR | News | Comments

SAN ANTONIO - A high level of circulating tumor cells (CTCs) - cells that have detached from a tumor and are circulating in the body through the blood - are an independent prognostic marker in metastatic breast cancer as first-line therapy. In addition, persistence of high CTC level...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading